BioSpace

Genetix’s genetic medicines are officially profitable, with $327M in sales YTD

It’s been a long road to financial stability for Genetix Biotherapeutics, the rebranded name of bluebird bio following its February 2025 sale to two private equity firms, but on Monday the biotech estimated full year 2026 sales will reach $500 million.

By BioSpace

1 min read
Genetix’s genetic medicines are officially profitable, with $327M in sales YTD
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights